KLRS
Kalaris Therapeutics, Inc.
NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY
$1.66
-12.63% today
Updated 2026-11-12
Market cap
$48.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.02
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-0.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$17.67
+964.46%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -0.80 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-11.43M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-15.48M | $-14.70M | $-58.77M | $-43.44M | $-11.52M |
| EPS | — | — | — | — | $-2.02 |
| Free cash flow | $-9.78M | $-14.13M | $-67.70M | $-43.18M | $-11.43M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Kalaris Therapeutics, Inc. trades at $1.66. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.80, it sits in the distress.
Frequently asked questions
What is Kalaris Therapeutics, Inc.'s stock price?
Kalaris Therapeutics, Inc. (KLRS) trades at $1.66.
Is Kalaris Therapeutics, Inc. overvalued?
Kalaris Therapeutics, Inc. carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Kalaris Therapeutics, Inc. (KLRS)?
The 12-month analyst consensus target is $17.67, about 964.5% above the current $1.66. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Kalaris Therapeutics, Inc.'s Altman Z-Score is -0.80, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-64.32%
Beta—
50D MA$2.86
200D MA$5.33
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—